Matching slides 14,162
Current window 10,531-10,560
Pages 473
Rows per page 30
Slide function: Expose Contradictionclear collectionreset all

Slide function

10,531-10,560 of 14,162

filter-aware
163
The slide uses direct quotes to expose a misalignment between the stated value proposition (reduced hospitalization) and the actual usage (scheduling convenience).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
164
The slide uses a primary headline followed by a detailed supporting quote, highlighting the ethical and financial concerns regarding off-label use of perfusion technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
166
The slide uses direct quotes from UCSF hospital administrators to frame the argument that TransMedics usage is being curtailed due to cost and lack of clinical indication.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
167
Uses direct quotes from surgeons at Utah and UCSD to support the thesis of off-label, convenience-driven usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
168
The slide uses direct quotes to highlight a discrepancy between the purported clinical value of the device and the actual operational use case.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
169
The slide uses direct quotes from anonymous experts to build a case of 'expensive abuse' of medical technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
170
The slide uses a Q&A transcript format to build a case against the clinical justification of the product's usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
171
The slide uses expert quotes to frame 'back to base' usage as a potentially harmful, off-label practice driven by convenience rather than clinical necessity.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
172
The slide uses a Q&A format to highlight a specific industry pain point regarding the misuse of medical technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
173
The slide highlights a specific operational failure (delayed pump usage) causing a 10% loss rate in the region.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
174
The slide contrasts the author's claims of widespread off-label use with the official FDA 'Indications for Use' text.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
175
The slide uses a 'villain_critique' approach by quoting an ex-employee to expose what the author considers to be fraudulent medical claims.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
176
The slide uses a table from a JAMA Surgery paper to highlight the mean donor age in the trial (45.9 years) as evidence of selection bias.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
179
The slide uses a Q&A transcript format to highlight the discrepancy between regulatory guidelines and real-world surgical behavior.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
180
The slide uses a specific study to challenge the safety/efficacy claims of machine perfusion vendors like TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
181
The slide uses a combination of narrative summary and verbatim Q&A transcripts to highlight discrepancies between trial conditions and real-world usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
183
The slide uses direct quotes from a transplant surgeon to expose potential malpractice or dangerous usage patterns.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
184
The slide uses a Q&A transcript format to frame the company's business model as 'quackery' and reliant on 'marginal' organs.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
185
The slide uses a 'villain' narrative style to frame the company's business practices as risky or non-compliant.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
186
The slide uses expert testimony to challenge the value proposition of the TransMedics technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
187
The slide uses a direct quote from a surgeon to highlight a perceived contradiction in the company's marketing claims.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
188
The slide uses a Q&A format to expose that the device is being used for high-risk, 'reckless' practices rather than standard clinical indications.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
189
The slide uses a Q&A transcript format to substantiate claims of fraud and kickbacks.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
190
The slide uses a Q&A format to highlight a specific allegation of unethical pressure to over-utilize a medical device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
191
The slide uses expert testimony to contradict the manufacturer's regulatory compliance claims.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
192
The slide uses a Q&A transcript format to build a case against the company's stated compliance.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
194
The slide uses direct quotes from a former executive to highlight perceived operational failures and poor talent quality at TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
196
The slide uses direct quotes from a transplant surgeon to validate the claim of incompetence and poor operational performance.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
197
The slide uses a Q&A format to highlight specific allegations of surgical incompetence and device-related risks.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
198
The slide uses a Q&A format to present a negative expert opinion on TransMedics' clinical quality and hiring standards.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit